CBC Group believes the maturing market for innovative products in Greater China represents an opportunity sufficient to support its launch of R-Bridge, the first discrete fund dedicated to non-dilutive investments in royalty streams and credit...

Concarlo is developing targeted therapies for metastatic breast cancer that take aim at both CDK4/6-driven cell proliferation and CDK2-driven drug resistance in one go.  The company spun out of SUNY...

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Tuesday for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections...

As Zai Lab Ltd. (NASDAQ:ZLAB) prepares for its first product launch, more clinical work and additional deals to fortify its pipeline, the company passed on the chance to list on Hong Kong’s new biotech chapter,...

FDA's Antimicrobial Drugs Advisory Committee voted in favor of IV and oral formulations of omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The amniomethylcycline antibiotic's PDUFA date is in early October. The panel voted that there is...

FDA's Antimicrobial Drugs Advisory Committee scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibiotic to treat...

FDA's Antimicrobial Drugs Advisory Committee has scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibiotic to...

TECHNOLOGY: Targeting domains; other Circular single-stranded DNA (CSSD)-based PTK7-targeting aptamers could be used to deliver cancer therapies. The aptamers consist of CSSD engineered to target PTK7 -- a protein expressed on many cancers -- and...

FDA accepted and granted Priority Review to two NDAs from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) for omadacycline to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA dates are...

FDA accepted and granted Priority Review to two NDAs from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) for omadacycline to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA dates are...